Effect of Tiotropium on sputum and cough in COPD patients with prolonged sputum

Not Applicable

Recruiting

• Conditions: Outpatients of Chronic Obstructive Pulmonary Disease (COPD)

• Registration Number: JPRN-UMIN000005139
• Lead Sponsor: Tokyo Women's Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-03-01
• Study Completion: 2011-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients whose dose of antibiotics, steroid, 2 stimulant, anti-cholinergic agent, theophylline preparation or expectorant was changed within 1 month before the screening test. 2) Patients who began treatment with an ACE inhibitor or whose dose of ACE inhibitor was changed within 1 month before the screening test. 3) Patients with recent onset of upper airway infection (i.e. within 1 month before the screening test). 4) Patients with a history of hypersensitivity to the components of Tiotropium Respimat 5) Patients with contraindication of Tiotropium Respimat. 6) Other than the above, patients judged by the investigator to be inappropriate as the subjects of study. 7) Patients with alcohol or drug abuse. 8) Patients who are unable to utilize spirometry 9) Patients who were judged not to be eligible for enrollment by the investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified